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Purpose: Synovitis is evident in a substantial subpopulation of
patients with early osteoarthritis (OA) and has been associated with
development of pathophysiology. Recently we have shown that adi-
pose-derived stem cells (ASC) inhibit joint destruction after local
application to knee joints with experimental OA. We now explored the
effect of synovitis on the immunomodulatory capacity of ASCs after
local administration in two experimental OA models differing in
synovitis.
Methods: ASCs were isolated from fat surrounding the popliteal lymph
nodes. ASCs were injected into knee joints after induction of collage-
nase-induced OA (CiOA) characterized by synovitis and surgically
induced destabilized medial meniscus (DMM)model inwhich synovitis
is scant. Synovial activation, chondrogenesis in ligaments and osteo-
phytes were measured using histology. Cytokines in synovial washouts
and serumwere determined using Luminex. Active TGFbwas measured
using the CAGAluc assay.
Results: ASCs injected into knee joints at different time-points after
induction of DMM (day 7, day 14 or day 7 and day 14) had no effect
on development of ligament damage or osteophyte formation. In
contrast, ASC treatment of collagenase-induced OA knee joints, rap-
idly inhibited synovitis and ligament damage when administered at
day 7 after induction. Washouts of synovium taken at different time
points after injection of ASCs (6 hrs, day 2, day 14 and day 42)
showed signiﬁcantly decreased levels of IL-1b and S100A8/A9
already at 48 hrs after ASC treatment. No effect was found on levels
of active TGFb. Serum levels of S100A8/A9 were signiﬁcantly
decreased (85% lower) at day 14 whereas IL-1 levels were not
detectable anymore at that time-point. Next, we explored the effect
in CiOA in a condition with less synovial inﬂammation. Synovial
thickness at day 42 was 62% lower when compared to the former
study. Injection of the same dose of ASCs at day 7 after induction of
CiOA, only marginally inhibited synovial thickening when measured
at day 42. Serum levels of S100A8/A9 were low at day 14 (around 50
ng/ml compared to 800 ng/ml in the ﬁrst experiment) and were not
altered by the ASC treatment. Chondrogenesis in collateral and cru-
ciate ligaments but also osteophyte formation at the bone margins
was also not diminished.
Conclusions: Synovial activation rapidly drives anti-inﬂammatory
effects of ASCs after local administration in murine OA knee joints with
synovitis protecting against development of ligament damage and
osteophyte formation.
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Purpose: Several recent studies suggested that a progenitor cell pop-
ulation which resides in cartilage exhibits stem cell relevant markers,
shows a phenotypic plasticity and generates chondrogenic, adipogenic,
and osteogenic lineages. They also provided some evidences of a stem/
progenitor cell niche within the articular cartilage. However, there is
still no deﬁnitive identity of these cells understood clearly in terms of
their surface markers and speciﬁc characters. The aim of this study is to
identify and characterize stem/progenitor cells exist in adult articular
cartilage in rats based on their differences in surface marker expression
before culture expansion.
Methods: Chondrocytes were isolated from rat adult cartilage in a
conventional manner using a collagenase treatment. Isolated cells were
subjected to ﬂow cytometry to investigate expression pattern of
selected surface markers of mesenchymal stem cells (CD29, CD34,
CD44, CD49e, CD73, CD90, CD105, CD106 and CD166). MSCs markers
which showed low expression in chondrocytes were used to sort out a
sub-population of cells, which was assumed to be a stem/progenitor
cells in the cartilage. The sub-population of cells isolated was furtherexamined for cell identity, multipotent differentiation ability, telomer-
ase activity and surface marker proﬁles.
Results: Analysis for the MSCs markers revealed that CD49e and CD90
were not expressed highly in uncultured rat chondrocytes. Rare pop-
ulations of CD49e- or CD90-positive cells were isolated successfully
showed better proliferation ability than unsorted total population of
cells. In particularly, they showed differentiation potential into different
lineages; CD49e-positive cells had higher adipogenic potential, and
CD90-positive cells had higher chondrogenic potential than each other.
They also expressed most of MSCs markers on their surface but the
expression level of CD49e and CD90 was decreasing along with pas-
sages after monolayer culture. Immunohistochemical analysis showed
that CD49e-positive cells lined particularly along the superﬁcial layer of
rat articular cartilage.
Conclusions: These results suggest that CD49e-positive and/or CD90-
positive cells could be a stem/progenitor cells in rat articular cartilage.
Further studies are needed to prove their identity and physiological role
in vivo.
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a- Purpose: Among the degenerative diseases associated with aging,
osteoarthritis (OA) is the most common pathology which affects 16% of
the female population over 65 years. ASC are adult stem cells exhibiting
functional properties that have open the way for cell-based clinical
therapies. Primarily, their capacity of multilineage differentiation has
been explored in a number of strategies for skeletal tissue regeneration.
More recently, ASC have been reported to exhibit immunosuppressive
as well as healing capacities, to improve angiogenesis and prevent
apoptosis or ﬁbrosis through the secretion of paracrine mediators. Up to
now, no therapeutic option exists to obtain a sustainable improvement
of joint function beside knee arthroplasty. This prompted us to propose
adipose-derived mesenchymal stromal cells (ASC) as a possible cell
therapy.
b-Methods: We used 2 pre-clinical models of OA, and showed that a
local injection of ASC allowed a reduction of synovitis, reduction of
osteophytes, joint stabilization and reduction of the osteoarthritic score.
This work was completed by toxicology data showing the excellent
tolerance of the local injection of ASC and biodistribution showing the
persistence of cells after 6 months in immunodeﬁcient murine model.
In addition, quality control and tolerability of the injection of ASC led to
the approval by AFSSAPS in France and by the PEI in Germany to con-
duct the phase I clinical trial. The patient received a single injection of
autologous ASC, 15 days after lipoaspiration (2.106, 107 or 5.107 cells)
through intra-articular injection.
c- Results: The ADIPOA project started in January 2010 with the goal to
develop a new cell-based strategy for patients suffering from knee OA.
In this open-label phase I trial, we included 18 patients with severe OA
of the knee in failure of conventional therapies (62.5% were KL IV) at
two sites, Montpellier and Wurzburg. Mean age was 61 years, with a 10
years history of knee OA. The primary outcomemeasure of effectiveness
was patient-reported WOMAC pain subscores by VAS in the affected
knee at week 12. Secondary outcome measures included Outcome
Measures in Rheumatology Clinical Trials and Osteoarthritis Research
Society International (OMERACT OARSI) responses. We observed a
decrease of the VAS Pain (7311 mm day 0 to 3223 month 3), and of
WOMAC (5018 to 257 month 3).
d-Conclusions: This study conﬁrms the feasibility and safety of local
injection of autologous cells from adipose tissue and suggests that the
most effective dose was 107 autologous cells.The ADIPOA research
teams performed successfully the phase I clinical trial in France and
Germany. A phase IIB controlled trial is scheduled to conﬁrm the clinical
beneﬁt of this strategy.
